Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with...

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Patients with type 2 diabetes exhibit increased susceptibility to prolonged QT intervals.
• Insulin secretagogues, used for diabetes treatment, can prolong the QT interval and potentially trigger arrhythmias.

Purpose of the Study:

• To evaluate the effect of secretagogues on the QTc interval during cardiac stress testing in type 2 diabetes patients.
• To investigate whether secretagogue use alters the normal physiological decrease in QTc interval during cardiac stress.

Main Methods:

• Electrocardiogram (ECG) stress tests were performed on 20 type 2 diabetes patients treated with secretagogues.
• QTc intervals were measured before cardiac stress test (BCST) and at the acme of cardiac stress test (ACST).
• Comparison groups included patients treated with metformin only and a control group.

Main Results:

• Diabetic patients on secretagogues had longer QTc-ACST values compared to those on metformin alone.
• Unlike the control group, diabetic patients on secretagogues did not exhibit the typical QTc shortening during stress.
• Diabetic patients on secretagogues showed a significant QTc prolongation from BCST to ACST.

Conclusions:

• Diabetic patients treated with secretagogues do not display the protective physiological QTc decrease during cardiac stress.
• These findings highlight the need to assess QT interval length in type 2 diabetes patients on secretagogues, even during routine cardiac stress tests.
• Consideration of secretagogue-induced QT prolongation is crucial for arrhythmia risk assessment in diabetic patients.